Sign In   |   Register
News: Congress

EAS 2018 Video interview: Professor Brian A. Ference on Lipoprotein (a)

Monday 7 May 2018   (1 Comments)
Share |

Lipoprotein(a) has been a focus of news at EAS Congress Lisbon 2018. Professor Brian A. Ference (Director of Research in Translational Therapeutics, the University of Cambridge, and Benjamin Meaker Visiting Professor, the University of Bristol, UK) discusses the rationale, key findings and implications from a timely Mendelian randomization analysis which aimed to address the question: How much does lipoprotein(a) need to be lowered for a clinically relevant effect?

Comments...

Gert Kostner says...
Posted Wednesday 9 May 2018
We have two comments: 1. The calculations proposed by Bryan Ference miss one important issue: There is no cut-off point for Lp(a) mentioned. Obviously a firm cut-off level may not be provided at the moment but there is ample literature available indicating that Lp(a) levels below 30 mg/dl are rather safe. On the other hand Lp(a) may rise quite substantially even in these individuals under certain disease in particular in nephrotic syndrome patients. In an case it may not be appropriate to try to lower Lp(a) in individuals with Lp(a) < 30 mg/dl. 2. The suggestion that 38.7 mg/d/L difference in LDL-C might have the same effect as 100 mg/dl of Lp(a) is certainly an average estimate and does not apply for individual patients. It should also be mentioned that 100 mg/dl Lp(a) correspond to roughly 38.5 mg/dl of Lp(a)-C and thus the effect of lowering Lp(a) in mass units of cholesterol is equal tot hat of LDL applying the data from the study of Bryan. Karam Kostner and Gert Kostner

Membership Software Powered by YourMembership  ::  Legal